Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Joined May 2009
- Tweets 118,906
- Following 2,004
- Followers 49,870
- Likes 11,560
23,757 Photos and videos
Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis. @harrisoncn1 @GSTTnhs @EHA_Hematology #EHA2026 #hematology #oncology
onclive.com/view/inca033989-…
1
2
2
333
11h
The type II JAK2 inhibitor AJ1-11095 produced SVRs, deep symptom responses, and mutation VAF reductions in type I JAK inhibitor–exposed myelofibrosis. @TischCancer @IcahnMountSinai @EHA_Hematology #EHA2026 #hematology #oncology
onclive.com/view/aj1-11095-s…
4
305
11h
EPCORE DLBCL-1: @EHA_Hematology #EHA2026: Epcoritamab outperformed investigator’s choice of CIT in relapsed/refractory large B-cell lymphoma, improving PFS and delivering durable complete responses.
✅ Higher CR rate
✅ More durable remissions
✅ 27% PFS at 3 years
Read more: onclive.com/view/epcoritamab…
2
339
12h
📢 @EHA_Hematology #EHA26: Talquetamab-based combinations delivered impressive results in R/R #myeloma.
✅ Up to 72% reduction in risk of progression or death
✅ Higher CR and MRD-negative CR rates
✅ Clinically meaningful OS improvement trends
Could Tal-Dara combinations become a new standard as early as first relapse? 🔗onclive.com/view/monumental-…
1
1
331
12h
🩸@EHA_Hematology #EHA2026 update: A first-in-class, switchable allogeneic #CAR_T therapy showed encouraging activity in R/R #AML.
✅ CR/CRh responses, including MRD-negative remissions
✅ No GVHD or ICANS reported
✅ Phase 1b enrollment underway
Read more: onclive.com/view/switchable-…
1
266
13h
Back in 2025, we learned that the INDEPENDENCE trial narrowly missed its primary end point.
At #EHA2026, investigators dived into the full data. Read more on the phase 3 findings for luspatercept in myelofibrosis-associated anemia @EHA_Hematology #mpnsm #oncology onclive.com/view/luspatercep…
1
2
297
15h
Fixed-duration venetoclax plus obinutuzumab maintained a PFS benefit vs chlorambucil/obinutuzumab in patients with previously untreated CLL in the final analysis of the phase 3 CLL14 trial @EHA_Hematology #EHA2026 #leusm #oncology onclive.com/view/cll14-final…
1
1
291
16h
We're getting so many amazing expert insights and groundbreaking data at day 3 of #EHA2026‼️
Keep checking back to our site for coverage of the conference👀
@EHA_Hematology #lymsm #mmsm #leusm #oncology #cancer #hematology
2
3
419
17h
📈ALL expert, @RyanCassaday of @fredhutch ranked these headlining #EHA2026 abstracts in ALL.
‼️Visit our site for in-depth, expert-informed coverage of all these abstracts and more.
@EHA_Hematology #leusm #oncology #hematology #cancer #cancercare
2
5
874
Jun 12
WATCH:
@MarkTysonMD of @MayoUrology discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC. #oncology #NMIBC #bladdercancer
hubs.li/Q04lhhqw0
1
293
Jun 12
That's a wrap on day 2 of #EHA2026‼️Thank you to all the experts that spoke with us today‼️
Don't miss out on all the groundbreaking data shared toady and check out our site for in-depth, expert-informed coverage‼️
@EHA_Hematology #lymsm #leusm #mmsm #oncology #hematology
3
5
529
Jun 12
Topline results from the phase 3 LAGOON trial showed that lurbinectedin, alone or in combination with irinotecan, missed the primary OS end point in patients with relapsed small cell lung cancer. 📊
Read more ➡️ hubs.li/Q04lh0l80
#LungCancer #SCLC #ThoracicOncology #ClinicalTrials #DrugDevelopment #Oncology #MedTwitter
355
Jun 12
WATCH: Jiong Wu, MD, PhD, discusses the significance of studying iza-bren in a phase 3 setting in unresectable, locally advanced or metastatic TNBC. @ASCO #ASCO26 #bcsm #oncology
onclive.com/view/dr-wu-on-th…
2
236
Jun 12
Subgroup analyses from the AUGMENT-101 trial showed revumenib produced clinically meaningful responses across groups of patients with relapsed/refractory, NPM1-mutated AML and high-risk co-mutation profiles, as well as pediatric and young adult patients with KMT2A-rearranged acute leukemia #lymsm #oncology
Dive into the @EHA_Hematology #EHA2026 data here: onclive.com/view/subgroup-an…
2
2
245
Jun 12
BREAKING: @FDAOncology Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC #oncology #pcsm #FDAapproved
Learn more about the data supporting this regulatory decision: hubs.li/Q04ldDMp0
261
Jun 12
ESR1 mutation testing in metastatic breast cancer is evolving fast — and so are the clinical questions around it. Pedram Razavi, MD, PhD and Dara S. Ross, MD break down what's changing and what it means for management.
Read the full OncLive® coverage:
hubs.li/Q04kYqrw0
@PedramRazaviMD @MSKCancerCenter
#BreastCancer #ESR1 #mBC
256
Jun 12
BREAKING 🚨: @FDAOncology Approves Adjuvant Belzutifan Plus Pembrolizumab in RCC
Learn more about the data supporting this regulatory decision 📰➡️ onclive.com/view/fda-approve…
#FDAapproved #kcsm #oncology
1
264
Jun 12
WATCH: Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma. @HeadNeckMD @harvardmed @DanaFarber @ASCO #ASCO26 #hncsm #oncology
onclive.com/view/dr-hanna-on…
1
3
284
Jun 12
Daraxonrasib monotherapy as a frontline option in metastatic PDAC — phase 1/2 data from AACR 2026 show promising tumor response and disease control in RAS-mutated disease. Read the OncLive® coverage from Eileen M. O'Reilly, MD.
hubs.ly/Q04kZGkb0
@EileenMOReilly @MSKCancerCenter #PancreaticCancer #AACR2026 #GIOnc
1
2
3
411